To the editor

JAMA

Volumn 300, Issue 24, 2008, Pages 2855-

  Kara, Ozgur ^a   Dizdar, Omer ^a   Altundag, Kadri ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; DRUG DERIVATIVE; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; BRAIN TUMOR; CANCER ASSOCIATED ANEMIA; CARDIOVASCULAR RISK; DISEASE ASSOCIATION; HUMAN; LETTER; PANCREAS CANCER; PRIORITY JOURNAL; VENOUS THROMBOEMBOLISM; NEOPLASM; NOTE; RISK;

ANEMIA; ERYTHROPOIETIN; ERYTHROPOIETIN, RECOMBINANT; HEMATINICS; HUMANS; NEOPLASMS; RISK; VENOUS THROMBOEMBOLISM;

EID: 58149286551     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2008.869     Document Type: Letter

References (2)

1. Bennett CL, Silver SM, Djulbegovic B, et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA. 2008;299(8):914-924.
2. Thodiyil PA, Kakkar AK. Variation in relative risk of venous thromboembolism in different cancers. Thromb Haemost. 2002;87(6):1076-1077.